ArticleToxicology reports2025
Transplacental and genotoxicity effects of thallium(I) during organogenesis in mice.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased concentration of thallium (Tl) in the environment is a cause for concern because the entire population, including pregnant women, is exposed, and this metal crosses the placenta and reaches the conceptus during development. In biological models such as mice, some abnormalities and delays in ossification occur in the fetuses of mice administered Tl on day 7 of gestation, but exposure to environmental Tl is constant during fetal development; therefore, in this study, the effects of several administrations of TI during organogenesis on the external morphology, skeletal development and genotoxicity of fetuses were evaluated. Four groups of 10 pregnant mice were administered 5.28, 6.16, 7.4 or 9.25 mg/kg body weight Tl(I) acetate intraperitoneally during fetal organogenesis. Additionally, samples were taken from fetuses from pregnant mice treated with 5.28 and 6.16 mg/kg body weight to evaluate the transplacental genotoxicity. The results revealed that the 9.25 mg/kg body weight dose produced maternal and fetal toxicity, and all of the treatment groups presented relatively high percentages of fetuses with external abnormalities, reduced bone ossification, and an increased percentage of liver cells with structural chromosomal aberrations (SCAs) and micronuclei (MNs) in blood cells. These results show that Tl(I) acetate administered during organogenesis produces abnormalities, including a delay in ossification and transplacental genotoxicity, in mouse fetuses. These findings are important because Tl has negative effects on development and may affect the health of offspring in the future because it can damage genetic material.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.